Borrelia antigens

a technology of borrelia and antigens, applied in the field of isolated nucleic acid molecules, can solve the problems of withdrawn from the market, high cost of preventing the disease, autoimmune reactions, etc., and achieve the greatest potential of preventing lyme borreliosis

Inactive Publication Date: 2013-05-09
INTERCELL AG
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0018]There have been concerns to develop an inactivated whole cell vaccine for humans, because of the potential risk that it may induce cross-reactive antibodies to human antigens. Therefore, subunit vaccines are considered to have the greatest potential in preventing Lyme borreliosis.

Problems solved by technology

Thus, these OspA antibodies produced by vaccination are not used to fight infection in the body.
However, shortly after LYMErix™ was commercially available, it was withdrawn from the market in 2002.
Some of the reasons are the need for booster injections every year or every other year, relatively high cost of this preventive approach compared with antibiotic treatment of early infection.
In addition, there was a theoretical and never proven concern that LYMErix™ could cause autoimmune reactions in a subgroup of the population.
More particularly, the problem was to provide an efficient, relevant and comprehensive set of nucleic acid molecules, proteins, hyperimmune serum reactive antigens or antigens from B. burgdorferi s.l. that can be used for the manufacture of said medicaments.
A still further problem was to provide methods and means for producing a protein, an hyperimmune reactive antigen or an antigen, or a fragment thereof, for identifying an antagonist capable of reducing or inhibiting the interaction activity of such protein, hyperimmune reactive antigen or antigen with an interaction partner thereof and preferably an antibody directed thereagainst, for treating infections, for immunizing an animal or man.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Borrelia antigens
  • Borrelia antigens
  • Borrelia antigens

Examples

Experimental program
Comparison scheme
Effect test

example 1

General Screening Procedure for the Identification of the Peptides According to the Present Invention

[0296]The approach, which has been employed for the present invention, is based on the interaction of proteins or peptides encoded by B. burgdorferi s.l. with the antibodies present in human sera. The antibodies produced against B. burgdorferi s.l. by the human immune system and present in human sera are indicative of the in vivo expression of the antigenic proteins and to their immunogenicity. In addition, the antigenic proteins as identified by the bacterial surface display expression libraries using pools of pre-selected sera, are processed in a second and third round of screening by individual selected or generated sera. Thus the present invention supplies an efficient, relevant, comprehensive set of antigens as a pharmaceutical composition, especially a vaccine preventing infections caused by B. burgdorferi s.l.

[0297]In the antigen identification program for identifying a compre...

example 2

Characterization and Selection of Human Serum Sources Based on Anti-B. burgdorferi s.l. Antibodies, Preparation of Antibody Screening Reagents

Experimental Procedures

Enzyme-Linked Immunosorbent Assay (ELISA).

[0309]ELISA plates (Maxisorb, Millipore) were coated with 5-10 μg / ml total protein diluted in coating buffer (0.1 M sodium carbonate pH 9.2). For whole cell ELISA, 106 biotin-labelled and fixed bacteria were added to Streptavidin-coated ELISA plates. Two dilutions of sera (10,000×, 50,000×) were made in PBS-BSA. Highly specific Horse Radish Peroxidase (HRP)-conjugated anti-human IgG secondary antibodies (Southern Biotech) were used according to the manufacturer's recommendations (dilution: 1,000×). Antigen-antibody complexes were quantified by measuring the conversion of the substrate (ABTS) to coloured product based on OD405 nm readings by automatic ELISA reader (TECAN SUNRISE).

Preparation of Bacterial Antigen Extracts.

[0310]Total bacterial lysate: The B. burgdorferi s.s. strain...

example 3

Generation of Highly Random, Frame-Selected, Small-Fragment, Genomic DNA Libraries of B. burgdorferi s.l.

Experimental Procedures

Preparation of Genomic DNA.

[0316]Cells from a 400 ml bacterial culture were harvested (5,000 rpm, 20 min, room temperature), washed with 80 ml 50 mM Tris pH 7.4 and re-suspended in 10 ml 50 mM Tris pH 7.4 / 25% Sucrose / 50 mM EDTA. The suspension was transferred to a fresh glass tube and Lysozyme (final conc.: 1.5 mg / ml) and SDS (final conc.: 2%) were added. The tube was incubated on ice for cell lysis. Proteinase K (final conc.: 0.1 mg / ml) was added and incubated for 10 min at 37° C., followed by Phenol / Chloroform (1:1) extraction, which was performed several times. A final extraction step was performed with Chloroform / Isoamylalcohol (1:24) to remove Phenol traces. The sample was treated with RNase A (final conc.: 10 μg / ml) for 1 h at room temperature and Phenol / Chloroform and Chloroform / Isoamylalcohol extractions were performed as described above. DNA in the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
lengthaaaaaaaaaa
immunogenic compositionaaaaaaaaaa
Login to view more

Abstract

The present invention relates to an isolated nucleic acid molecule encoding a protein, preferably a hyperimmune serum-reactive antigen from Borrelia, a vector comprising such nucleic acid molecule, a host cell comprising such vector, a protein, preferably a hyperimmune serum-reactive antigen from Borrelia, a process for producing such protein, a process for producing a cell which expresses such protein, an antibody that binds to such protein, a hybridoma cell producing such antibody, a method for producing such antibody, a pharmaceutical composition comprising such nucleic acid molecule, protein, or antibody, use of such nucleic acid molecule, protein, or antibody for the manufacture of a medicament, a method for identifying an antagonist capable of reducing or inhibiting the activity of such protein, a method for diagnosis or treatment of an infection with a pathogen causing Lyme disease or an infection with Borrelia burgdorferi s.l.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application a divisional of U.S. application Ser. No. 13 / 410,915, filed Mar. 2, 2012, which is a divisional of U.S. application Ser. No. 12 / 440,161, filed Jul. 21, 2009, now U.S. Pat. No. 8,129,165, which is the U.S. National Stage of International Application No. PCT / AT2007 / 000439, filed Sep. 14, 2007, which claims benefit of European Application No. 06019384.4, filed Sep. 15, 2006, each of which is hereby incorporated by reference.FIELD OF THE INVENTION[0002]The present invention relates to isolated nucleic acid molecules which encode a protein, isolated nucleic acid molecules which encode a hyperimmune serum reactive antigen, a vector which comprises such nucleic acid molecule, a host cell comprising such vector, a hyperimmune reactive antigen from Borrelia species, proteins which are preferably hyperimmune serum reactive antigens, hyperimmune serum reactive antigens, antigens, a process for producing such proteins, hyperimmune se...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K7/08C07K7/06
CPCA61K39/00A61K2039/53C07K7/08C07K7/06C07K14/20A61P31/04A61P37/04Y02A50/30
Inventor LUNDBERG, URBANMEINKE, ANDREASNAGY, ESZTERVON GABAIN, ALEXANDERNOIGES, BIRGITGELBMANN, DIETERPOLJAK, ALBINATRISKA, CHRISTINE
Owner INTERCELL AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap